Article
Biochemistry & Molecular Biology
Teodor Salmen, Ali Abbas Rizvi, Manfredi Rizzo, Valeria-Anca Pietrosel, Ioana-Cristina Bica, Cosmina Theodora Diaconu, Claudia Gabriela Potcovaru, Bianca-Margareta Salmen, Oana Andreia Coman, Anca Bobirca, Roxana-Adriana Stoica, Anca Stoian
Summary: In this retrospective study, both SGLT-2i and GLP-1 RAs showed efficacy in weight control, metabolic control, and diastolic blood pressure control when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications in a real-life setting.
Article
Endocrinology & Metabolism
Feifei Zhou, Nannan Du, Lulin Zhou, Chenxi Wang, He Ren, Qiang Sun
Summary: This meta-analysis demonstrates that sotagliflozin has an acceptable safety profile in patients with diabetes, with adverse events including genital mycotic infection, related-to-acidosis events, diarrhea, volume depletion, and severe nocturnal hypoglycemia events. The subgroup analysis of sotagliflozin dosage is of great clinical significance for guiding the use of sotagliflozin in patients with diabetes in the future.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Darren K. Mcguire, Silvio E. Inzucchi, Renato D. Lopes, Michael J. Davies, Phillip Banks, Bertram Pitt, Philippe Gabriel Steg
Summary: This study assessed the efficacy of Sotagliflozin on heart failure clinical outcomes in individuals with different baseline glycosylated hemoglobin levels. The results showed that Sotagliflozin reduced heart failure outcomes, regardless of baseline HbA1c.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Santo Colosimo, Federico Ravaioli, Maria L. Petroni, Lucia Brodosi, Francesca Marchignoli, Francesca A. Barbanti, Anna S. Sasdelli, Giulio Marchesini, Loris Pironi
Summary: The study showed that GLP-1 receptor agonists and SGLT-2 inhibitors can improve biomarkers of steatosis and fibrosis, therefore slowing down the progression of liver disease.
LIVER INTERNATIONAL
(2021)
Article
Endocrinology & Metabolism
Fu-Chih Hsiao, Kun-Chi Yen, Tze-Fan Chao, Shao-Wei Chen, Yi-Hsin Chan, Pao-Hsien Chu
Summary: The study found that in a real-world practice, SGLT2is were associated with a lower risk of new-onset AF compared with GLP-1RAs among patients with type 2 diabetes mellitus.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Editorial Material
Endocrinology & Metabolism
Masanori Wakisaka, Kuniyuki Nakamura, Takanari Kitazono
Summary: SGLT2 is upregulated in mesangial cells and pericytes due to high glucose and ischemia, which can directly exacerbate ischemia in the kidney interstitial legion, heart, and brain. The overexpression of SGLT2 in these cells can lead to organ failures through damages or loss of capillaries and dysfunctions of mesangial cells, which can be attenuated by SGLT2 inhibitors.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2022)
Article
Medicine, General & Internal
Mukul Bhattarai, Mohsin Salih, Manjari Regmi, Mohammad Al-Akchar, Radhika Deshpande, Zurain Niaz, Abhishek Kulkarni, Momin Siddique, Shruti Hegde
Summary: This meta-analysis supports the effectiveness of SGLT2 inhibitors in improving cardiovascular morbidity and mortality in selected patients. However, SGLT2 inhibitors were not associated with a reduced risk of acute myocardial infarction. Future long-term prospective studies are needed to further understand the long-term cardiovascular benefits.
Review
Cardiac & Cardiovascular Systems
Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y. Q. Tan, Tiong-Cheng Yeo, Chi-Hang Lee, Weiqin Lin, Ching-Hui Sia
Summary: SGLT2 inhibitors have shown positive effects on cardiovascular outcomes in patients without diabetes mellitus, particularly in reducing cardiovascular deaths and heart failure hospitalizations in heart failure patients. Additionally, these inhibitors have beneficial metabolic effects, such as weight and blood pressure control, in patients without diabetes mellitus.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Endocrinology & Metabolism
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Mantzoros
Summary: This review provides an updated summary of the pharmacotherapeutic approach to type 2 diabetes (T2D), including the mechanism of action, administration details, side effect profile, cost, and use in specific populations of different classes of agents. It also reviews the targets of novel therapeutic T2D agent development. Finally, it outlines a contemporary treatment approach starting with the identification of an individualized glycemic control goal, followed by the selection, initiation, and further intensification of a personalized therapeutic plan for T2D.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Cardiac & Cardiovascular Systems
Husam M. Salah, Subhi J. Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J. Paul Mounsey, Stephen J. Greene, Darren K. McGuire, Renato D. Lopes, Marat Fudim
Summary: Nine randomized clinical trials involving 60,914 patients with type 2 diabetes showed that the use of SGLT2 and dual SGLT1/2 inhibitors can improve cardiovascular and kidney outcomes.
AMERICAN HEART JOURNAL
(2021)
Review
Health Care Sciences & Services
Jason T. Alexander, Erin M. Staab, Wen Wan, Melissa Franco, Alexandra Knitter, M. Reza Skandari, Shari Bolen, Nisa M. Maruthur, Elbert S. Huang, Louis H. Philipson, Aaron N. Winn, Celeste C. Thomas, Meltem Zeytinoglu, Valerie G. Press, Elizabeth L. Tung, Kathryn Gunter, Brittany Bindon, Sanjay Jumani, Neda Laiteerapong
Summary: SGLT2Is show durable reductions in cardiovascular risk factors compared to both placebo and other anti-hyperglycemic medications. Reductions in macrovascular complications and mortality were observed only in comparisons with placebo, with insufficient data for longer-term outcomes in comparisons with other anti-hyperglycemic medications. An increased risk of genital yeast infections was observed for both genders in comparisons with placebo and other anti-hyperglycemic medications.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo, Christopher Labos, Simon S. Wing, Stella S. Daskalopoulou
Summary: The aim of this umbrella review and meta-analysis was to evaluate the impact of diabetes on the risk of dementia and the effectiveness of antidiabetic treatments. The study found that metformin, thiazolidinediones, pioglitazone, GLP1RAs, and SGLT2is were associated with a reduced risk of dementia. However, further longitudinal studies are needed to determine their relative benefits in different populations.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Carolyn S. P. Lam, Chinthanie Ramasundarahettige, Kelley R. H. Branch, Naveed Sattar, Julio Rosenstock, Richard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth Niemoeller, Nardev S. Khurmi, Seungjae Baek, Hertzel C. Gerstein
Summary: The analysis of the AMPLITUDE-O trial suggests that the efficacy and safety of Efpeglenatide are not impacted by concurrent use of SGLT2 inhibitors. These data support the combined use of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
Article
Cardiac & Cardiovascular Systems
Robert J. H. Miller, Derek S. Chew, Lei Qin, Nowell M. Fine, Jieling Chen, John J. V. McMurray, Jonathan G. Howlett, Phil McEwan
Summary: This study compares the cost-effectiveness of immediate and 12-month delayed initiation of dapagliflozin treatment in patients with a history of hospitalization for heart failure from different healthcare perspectives. Using a decision-analytic Markov model, the study found that immediate initiation of dapagliflozin reduces heart failure events and cardiovascular mortality. Immediate initiation of dapagliflozin provides greater clinical benefits and should be considered standard of care.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Endocrinology & Metabolism
Bangjiaxin Ren, Ming Chen
Summary: This review evaluates the hypotensive efficacy of SGLT2 inhibitors in patients with hypertension and pre-hypertension. The results show that SGLT2 inhibitors significantly reduce blood pressure in patients, and the effect is further enhanced with increased drug dosage. This suggests that SGLT2 inhibitors have the potential to be used as antihypertensive agents in patients with hypertension complicated by type 2 diabetes.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
(2022)
